Study Purpose: This study aims to test a new drug called eloralintide to see if it helps people with persistent obesity lose weight safely. Some people in the study will get a placebo, which is a pill with no medicine, to compare results.

Participation: The study lasts about 80 weeks (that's a little over a year and a half). During this time, participants will need to be on stable incretin therapy, which is a type of treatment for diabetes. Incretin helps the body manage blood sugar.

Eligibility: To join, you need to have a body mass index (BMI) of at least 30, or 27 with health issues like high blood pressure or type 2 diabetes. You should not have had certain surgeries or procedures for weight loss recently. People with type 1 diabetes or recent heart problems cannot participate.

• Duration: The study lasts about 80 weeks.
• Eligibility: For people with obesity or overweight, with or without type 2 diabetes.
• Exclusions: Recent weight loss surgeries or certain medications disqualify participation.